Data on the rate of blood transfusions in phase III clinical trials are lacking, but we recommend erythrocyte transfusions when anemia provokes asthenia or hemoglobin falls to < 10 g/dL, or erythropoietin administration as a last resort, according to clinical judgement. This evidence concerns the gene EPO and anemia (phenotype).